Darzalex Faspro (daratumumab and hyaluronidase) significantly extended the time people with relapsed or refractory multiple myeloma live without…
Articles by Marisa Wexler, MS
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Blenrep (belantamab mafodotin-blmf), a first-in-class treatment…
The U.S. Food and Drug Administration (FDA) has given Celyad Oncology permission to begin a Phase 1 clinical…
A new research project aiming to better understand how fat cells help multiple myeloma cells resist treatment has won…
A combination of Sarclisa (isatuximab) plus standard Kyprolis (carfilzomib) and dexamethasone treatment significantly delays disease progression or…
A computer program developed by GNS Healthcare could be used to model and predict disease progression and response to…
The U.K.’s National Institute for Health and Care Excellence (NICE) has issued a draft “no” statement on the triple…
The European Commission (EC) has approved Sanofi‘s Sarclisa (isatuximab), in a triple combination with Pomalyst (pomalidomide)…
A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might…
A novel genetic test could help identify people with multiple myeloma who are at highest risk of aggressive disease and…